Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: A controlled study

Angelo Iacobellis, Massimo Siciliano, Francesco Perri, Brigida E. Annicchiarico, Gioacchino Leandro, Nazario Caruso, Laura Accadia, Giuseppe Bombardieri, Angelo Andriulli

Research output: Contribution to journalArticle

Abstract

Background/Aim: To evaluate long-term outcomes in decompensated HCV-related cirrhotic patients treated with antiviral therapy. Methods: Of 129 eligible patients, 66 received peginterferon alfa-2b and ribavirin for 24 weeks, and 63 were controls. Survival and recurrence of liver failure events after therapy were main outcomes. Results: Therapy was tolerated by 27 patients, dose reduced in 26 for toxicity, and discontinued in 13 for intolerance. End-of-therapy and sustained virological response (SVR) rates were 82.6% and 43.5% for HCV 2/3 patients, and 30.2% and 7.0% for HCV 1/4 patients. During therapy, odds ratios for severe infections or deaths due to infection were 2.95 (95% C.I. 0.93-9.3) and 1.97 (95% C.I. 0.40-9.51) in treated patients as compared with controls. During a follow-up of 30 months off-therapy, decompensated events occurred in 52, 33, and 3 of controls, non-responders, and SVR patients. Odds ratios for ascites, encephalopathy, and oesophageal bleeding in treated patients significantly decreased as compared with controls. Annualized incidence of death was 2.34, 1.91, and 0 per 1000 patient-years, respectively, in controls, non-responders, and SVR patients. Survival curves showed early separation of SVR patients from both non-responders and controls at approximately 6 months. Conclusions: In decompensated cirrhotics, HCV clearance by therapy is life-saving and reduces disease progression.

Original languageEnglish
Pages (from-to)206-212
Number of pages7
JournalJournal of Hepatology
Volume46
Issue number2
DOIs
Publication statusPublished - Feb 2007

Fingerprint

Ribavirin
Hepacivirus
Fibrosis
Therapeutics
peginterferon alfa-2b
Odds Ratio
Survival
Liver Failure
Brain Diseases
Infection
Ascites
Antiviral Agents
Disease Progression
Hemorrhage
Recurrence

Keywords

  • Antiviral therapy
  • Cirrhosis
  • HCV
  • Outcome
  • Peginterferon
  • Ribavirin

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis : A controlled study. / Iacobellis, Angelo; Siciliano, Massimo; Perri, Francesco; Annicchiarico, Brigida E.; Leandro, Gioacchino; Caruso, Nazario; Accadia, Laura; Bombardieri, Giuseppe; Andriulli, Angelo.

In: Journal of Hepatology, Vol. 46, No. 2, 02.2007, p. 206-212.

Research output: Contribution to journalArticle

Iacobellis, Angelo ; Siciliano, Massimo ; Perri, Francesco ; Annicchiarico, Brigida E. ; Leandro, Gioacchino ; Caruso, Nazario ; Accadia, Laura ; Bombardieri, Giuseppe ; Andriulli, Angelo. / Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis : A controlled study. In: Journal of Hepatology. 2007 ; Vol. 46, No. 2. pp. 206-212.
@article{272092fc6d2b403996fd7fcb454e2f29,
title = "Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: A controlled study",
abstract = "Background/Aim: To evaluate long-term outcomes in decompensated HCV-related cirrhotic patients treated with antiviral therapy. Methods: Of 129 eligible patients, 66 received peginterferon alfa-2b and ribavirin for 24 weeks, and 63 were controls. Survival and recurrence of liver failure events after therapy were main outcomes. Results: Therapy was tolerated by 27 patients, dose reduced in 26 for toxicity, and discontinued in 13 for intolerance. End-of-therapy and sustained virological response (SVR) rates were 82.6{\%} and 43.5{\%} for HCV 2/3 patients, and 30.2{\%} and 7.0{\%} for HCV 1/4 patients. During therapy, odds ratios for severe infections or deaths due to infection were 2.95 (95{\%} C.I. 0.93-9.3) and 1.97 (95{\%} C.I. 0.40-9.51) in treated patients as compared with controls. During a follow-up of 30 months off-therapy, decompensated events occurred in 52, 33, and 3 of controls, non-responders, and SVR patients. Odds ratios for ascites, encephalopathy, and oesophageal bleeding in treated patients significantly decreased as compared with controls. Annualized incidence of death was 2.34, 1.91, and 0 per 1000 patient-years, respectively, in controls, non-responders, and SVR patients. Survival curves showed early separation of SVR patients from both non-responders and controls at approximately 6 months. Conclusions: In decompensated cirrhotics, HCV clearance by therapy is life-saving and reduces disease progression.",
keywords = "Antiviral therapy, Cirrhosis, HCV, Outcome, Peginterferon, Ribavirin",
author = "Angelo Iacobellis and Massimo Siciliano and Francesco Perri and Annicchiarico, {Brigida E.} and Gioacchino Leandro and Nazario Caruso and Laura Accadia and Giuseppe Bombardieri and Angelo Andriulli",
year = "2007",
month = "2",
doi = "10.1016/j.jhep.2006.08.020",
language = "English",
volume = "46",
pages = "206--212",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier B.V.",
number = "2",

}

TY - JOUR

T1 - Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis

T2 - A controlled study

AU - Iacobellis, Angelo

AU - Siciliano, Massimo

AU - Perri, Francesco

AU - Annicchiarico, Brigida E.

AU - Leandro, Gioacchino

AU - Caruso, Nazario

AU - Accadia, Laura

AU - Bombardieri, Giuseppe

AU - Andriulli, Angelo

PY - 2007/2

Y1 - 2007/2

N2 - Background/Aim: To evaluate long-term outcomes in decompensated HCV-related cirrhotic patients treated with antiviral therapy. Methods: Of 129 eligible patients, 66 received peginterferon alfa-2b and ribavirin for 24 weeks, and 63 were controls. Survival and recurrence of liver failure events after therapy were main outcomes. Results: Therapy was tolerated by 27 patients, dose reduced in 26 for toxicity, and discontinued in 13 for intolerance. End-of-therapy and sustained virological response (SVR) rates were 82.6% and 43.5% for HCV 2/3 patients, and 30.2% and 7.0% for HCV 1/4 patients. During therapy, odds ratios for severe infections or deaths due to infection were 2.95 (95% C.I. 0.93-9.3) and 1.97 (95% C.I. 0.40-9.51) in treated patients as compared with controls. During a follow-up of 30 months off-therapy, decompensated events occurred in 52, 33, and 3 of controls, non-responders, and SVR patients. Odds ratios for ascites, encephalopathy, and oesophageal bleeding in treated patients significantly decreased as compared with controls. Annualized incidence of death was 2.34, 1.91, and 0 per 1000 patient-years, respectively, in controls, non-responders, and SVR patients. Survival curves showed early separation of SVR patients from both non-responders and controls at approximately 6 months. Conclusions: In decompensated cirrhotics, HCV clearance by therapy is life-saving and reduces disease progression.

AB - Background/Aim: To evaluate long-term outcomes in decompensated HCV-related cirrhotic patients treated with antiviral therapy. Methods: Of 129 eligible patients, 66 received peginterferon alfa-2b and ribavirin for 24 weeks, and 63 were controls. Survival and recurrence of liver failure events after therapy were main outcomes. Results: Therapy was tolerated by 27 patients, dose reduced in 26 for toxicity, and discontinued in 13 for intolerance. End-of-therapy and sustained virological response (SVR) rates were 82.6% and 43.5% for HCV 2/3 patients, and 30.2% and 7.0% for HCV 1/4 patients. During therapy, odds ratios for severe infections or deaths due to infection were 2.95 (95% C.I. 0.93-9.3) and 1.97 (95% C.I. 0.40-9.51) in treated patients as compared with controls. During a follow-up of 30 months off-therapy, decompensated events occurred in 52, 33, and 3 of controls, non-responders, and SVR patients. Odds ratios for ascites, encephalopathy, and oesophageal bleeding in treated patients significantly decreased as compared with controls. Annualized incidence of death was 2.34, 1.91, and 0 per 1000 patient-years, respectively, in controls, non-responders, and SVR patients. Survival curves showed early separation of SVR patients from both non-responders and controls at approximately 6 months. Conclusions: In decompensated cirrhotics, HCV clearance by therapy is life-saving and reduces disease progression.

KW - Antiviral therapy

KW - Cirrhosis

KW - HCV

KW - Outcome

KW - Peginterferon

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=33845647232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845647232&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2006.08.020

DO - 10.1016/j.jhep.2006.08.020

M3 - Article

C2 - 17125876

AN - SCOPUS:33845647232

VL - 46

SP - 206

EP - 212

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 2

ER -